Stable liquid compositions of netupitant and palonosetron
The present invention relates to stable liquid compositions suitable for parenteral administration in the form of a solution comprising: (a) netupitant and optionally palonosetron; (b) at least one pharmaceutically acceptable stabilizer; (c) at least one pharmaceutically acceptable solubilizer; and (d) at least one pharmaceutically acceptable vehicle, wherein netupitant is present at a concentration of about 0.5 mg/mL to about 20 mg/mL and the solution has a pH of about 2 to about 6. The compositions are suitable for subcutaneous, intravenous, or intramuscular administration. The invention further relates to methods for manufacturing the compositions and methods of using such compositions for prevention, treatment or management of nausea and vomiting.
1. A liquid pharmaceutical composition comprising:
(a) netupitant;
(b) at least one pharmaceutically acceptable stabilizer at a concentration of about 1.68 mg/mL to about 21.3 mg/mL selected from the group consisting of tromethamine, phosphoric acid, aspartic acid, tartaric acid, citric acid, maleic acid, ascorbic acid or mixtures thereof;
(c) at least one pharmaceutically acceptable solubilizer at a concentration of about 0.1 mg/mL to about 200 mg/mL selected from the group consisting of cyclodextrin, cyclodextrin derivatives, polysorbates, propylene glycol and mixtures thereof; and
(d) at least one pharmaceutically acceptable vehicle,
wherein netupitant is present at a concentration of about 0.5 mg/mL to about 20 mg/mL,
wherein the composition is in the form of a solution and has a pH of 2 to 6, and
wherein the solution is stable and suitable for parenteral administration.
2. The solution according to claim 1 , wherein the solution has an osmolality value of about 100 mOsm to about 500 mOsm.
3. The solution according to claim 1 , wherein the composition further comprises an antioxidant selected from the group consisting of butylated hydroxytoluene, monothioglycerol, sodium thiosulfate, sodium formaldehyde sulfoxylate and mixtures thereof.
4. The solution according to claim 1 , wherein the vehicle is selected from ethanol, water for injection or mixtures thereof.
5. The solution according to claim 1 , wherein the solution has netupitant N-oxide content of less than about 0.5% w/w with respect to total amount of netupitant in the solution after storage for 2 months at 25° C. and 60% relative humidity.
6. The solution according to claim 1 , wherein the solution is ready-to-use.
7. The solution according to claim 1 , wherein the solution is ready-to-dilute.
8. The solution according to claim 1 , wherein the solubilizer is present at a concentration ranging from about 0.5 mg/mL to about 100 mg/mL.
9. The solution according to claim 1 , wherein netupitant is present at a concentration of about 1.975 mg/mL.
10. A method of preventing acute and/or delayed nausea and/or vomiting associated with initial and/or repeat courses of cancer chemotherapy in a subject in need thereof comprising parenteral administration of the composition of claim 1 .
11. A liquid pharmaceutical composition comprising:
(a) active ingredients netupitant and palonosetron;
(b) at least one pharmaceutically acceptable stabilizer at a concentration of about 1.68 mg/mL to about 21.3 mg/mL selected from the group consisting of tromethamine, phosphoric acid, aspartic acid, tartaric acid, citric acid, maleic acid, ascorbic acid or mixtures thereof;
(c) at least one pharmaceutically acceptable solubilizer at a concentration of about 0.1 mg/mL to about 200 mg/mL selected from the group consisting of cyclodextrin, cyclodextrin derivatives, polysorbates, propylene glycol and mixtures thereof; and
(d) at least one pharmaceutically acceptable vehicle,
wherein netupitant is present at a concentration of about 0.5 mg/mL to about 20 mg/mL,
wherein palonosetron is present at a concentration at about 0.001 mg/mL or more;
wherein the composition is in the form of a solution and has a pH of 2 to 6, and
wherein the solution is stable and suitable for parenteral administration.
12. A method of preventing acute and/or delayed nausea and/or vomiting associated with initial and/or repeat courses of cancer chemotherapy in a subject in need thereof comprising parenteral administration of the composition of claim 11 .
13. The solution according to claim 11 , wherein the palonosetron is palonosetron hydrochloride.
14. The solution according to claim 11 , wherein palonosetron is present at a concentration of about 0.001 mg/ml to about 0.1 mg/mL.
15. The solution according to claim 11 , wherein the solution is physically stable and does not precipitate upon storage for at least 2 months at 25° C. and 60% relative humidity.
16. The solution according to claim 15 , wherein the solution is physically stable and does not precipitate upon storage for at least 2 months at 40° C. and 75% relative humidity.
17. The solution according to claim 11 , wherein the solution is suitable for intravenous bolus or infusion administration.
18. The solution according to claim 11 , wherein the composition further comprises an antioxidant selected from the group consisting of butylated hydroxytoluene, monothioglycerol, sodium thiosulfate, sodium formaldehyde sulfoxylate and mixtures thereof.
19. The solution according to claim 11 , wherein the vehicle is selected from ethanol, water for injection or mixtures thereof.
20. The solution according to claim 11 , wherein the solution has netupitant N-oxide content of less than about 0.5% w/w with respect to total amount of netupitant in the solution after storage for 2 months at 25° C. and 60% relative humidity.
21. The solution according to claim 11 , wherein the solution is ready-to-use or ready-to-dilute.
22. The solution according to claim 11 , wherein the solubilizer is present at a concentration ranging from about 0.5 mg/mL to about 100 mg/mL.
23. The solution according to claim 11 , wherein the solution is contained in a unit dosage form and comprises a total of 197.5 mg of netupitant and 0.28 mg of palonosetron hydrochloride, palonosetron being present as palonosetron hydrochloride in the unit dosage form.
24. The solution according to claim 11 , wherein netupitant is present at a concentration of about 1.975 mg/mL and palonosetron is present as palonosetron hydrochloride at a concentration of about 0.0028 mg/mL.